Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The full Galactic-HF data were supposed to have suggested a path forward. Instead they point the way to disagreement.
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.